Which has stronger valuation and earnings, CGEN or IBIO?

Compugen has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Compugen $74.00M 3.16 $35.34M $0.38 6.50 iBio $100K 774.94 -$33.04M -$0.34 N/A

Is CGEN or IBIO more profitable?

Compugen has a net margin of 47.56% compared to iBio's net margin of 0.00%. Compugen's return on equity of 42.57% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets Compugen 47.56% 42.57% 26.13% iBio N/A -40.66% -35.78%

Does the media prefer CGEN or IBIO?

In the previous week, Compugen had 3 more articles in the media than iBio. MarketBeat recorded 5 mentions for Compugen and 2 mentions for iBio. Compugen's average media sentiment score of 0.65 beat iBio's score of 0.37 indicating that Compugen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compugen 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IBIO or ELDN more profitable?

iBio's return on equity of -40.66% beat Eledon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -40.66% -35.78% Eledon Pharmaceuticals N/A -149.63% -50.84%

Does the media favor IBIO or ELDN?

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 2 mentions for iBio. Eledon Pharmaceuticals' average media sentiment score of 0.47 beat iBio's score of 0.37 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eledon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, IBIO or ADAG?

Adagene has higher revenue and earnings than iBio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iBio $100K 774.94 -$33.04M -$0.34 N/A Adagene $9.29M 24.17 -$17.61M N/A N/A

Is IBIO or ADAG more profitable?

Adagene's return on equity of 0.00% beat iBio's return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -40.66% -35.78% Adagene N/A N/A N/A

Does the media refer more to IBIO or ADAG?

In the previous week, Adagene had 8 more articles in the media than iBio. MarketBeat recorded 10 mentions for Adagene and 2 mentions for iBio. iBio's average media sentiment score of 0.37 beat Adagene's score of 0.31 indicating that iBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adagene 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor IBIO or TNXP?

In the previous week, Tonix Pharmaceuticals had 14 more articles in the media than iBio. MarketBeat recorded 16 mentions for Tonix Pharmaceuticals and 2 mentions for iBio. Tonix Pharmaceuticals' average media sentiment score of 0.71 beat iBio's score of 0.37 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tonix Pharmaceuticals 3 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IBIO or CAMP more profitable?

iBio has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. iBio's return on equity of -40.66% beat CAMP4 Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets iBio N/A -40.66% -35.78% CAMP4 Therapeutics -2,543.74% -252.79% -85.65%

Does the media favor IBIO or CAMP?

In the previous week, CAMP4 Therapeutics had 4 more articles in the media than iBio. MarketBeat recorded 6 mentions for CAMP4 Therapeutics and 2 mentions for iBio. CAMP4 Therapeutics' average media sentiment score of 0.84 beat iBio's score of 0.37 indicating that CAMP4 Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iBio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CAMP4 Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

iBio (IBIO) Competitors

$1.20 -0.02 (-1.63%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.24 +0.03 (+2.49%)

As of 09/11/2026 07:30 PM Eastern

Compare

IBIO vs. CGEN, ELDN, ADAG, TNXP, and CAMP

Should you buy iBio stock or one of its competitors? iBio's main competitors and comparable companies include Compugen (CGEN), Eledon Pharmaceuticals (ELDN), Adagene (ADAG), Tonix Pharmaceuticals (TNXP), and CAMP4 Therapeutics (CAMP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does iBio compare to Compugen?

Compugen (NASDAQ:CGEN) and iBio (NASDAQ:IBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Compugen has a beta of 2.78, meaning that its share price is 178% more volatile than the broader market. Comparatively, iBio has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Compugen has higher revenue and earnings than iBio. iBio is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$74.00M	3.16	$35.34M	$0.38	6.50
iBio	$100K	774.94	-$33.04M	-$0.34	N/A

12.2% of Compugen shares are held by institutional investors. Comparatively, 7.9% of iBio shares are held by institutional investors. 9.5% of Compugen shares are held by company insiders. Comparatively, 2.8% of iBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Compugen had 3 more articles in the media than iBio. MarketBeat recorded 5 mentions for Compugen and 2 mentions for iBio. Compugen's average media sentiment score of 0.65 beat iBio's score of 0.37 indicating that Compugen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Compugen	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Compugen has a net margin of 47.56% compared to iBio's net margin of 0.00%. Compugen's return on equity of 42.57% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
iBio	N/A	-40.66%	-35.78%

Compugen currently has a consensus price target of $5.00, suggesting a potential upside of 102.43%. iBio has a consensus price target of $5.00, suggesting a potential upside of 314.94%. Given iBio's stronger consensus rating and higher possible upside, analysts clearly believe iBio is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

Summary

Compugen beats iBio on 12 of the 17 factors compared between the two stocks.

How does iBio compare to Eledon Pharmaceuticals?

iBio (NASDAQ:IBIO) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

iBio's return on equity of -40.66% beat Eledon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%

iBio has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

7.9% of iBio shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 2.8% of iBio shares are held by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Eledon Pharmaceuticals had 1 more articles in the media than iBio. MarketBeat recorded 3 mentions for Eledon Pharmaceuticals and 2 mentions for iBio. Eledon Pharmaceuticals' average media sentiment score of 0.47 beat iBio's score of 0.37 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eledon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

iBio currently has a consensus target price of $5.00, indicating a potential upside of 314.94%. Eledon Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 259.71%. Given iBio's stronger consensus rating and higher probable upside, equities research analysts plainly believe iBio is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

iBio has higher revenue and earnings than Eledon Pharmaceuticals. iBio is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$100K	774.94	-$33.04M	-$0.34	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A

Summary

iBio beats Eledon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does iBio compare to Adagene?

iBio (NASDAQ:IBIO) and Adagene (NASDAQ:ADAG) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

In the previous week, Adagene had 8 more articles in the media than iBio. MarketBeat recorded 10 mentions for Adagene and 2 mentions for iBio. iBio's average media sentiment score of 0.37 beat Adagene's score of 0.31 indicating that iBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adagene	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.9% of iBio shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 2.8% of iBio shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Adagene has higher revenue and earnings than iBio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$100K	774.94	-$33.04M	-$0.34	N/A
Adagene	$9.29M	24.17	-$17.61M	N/A	N/A

Adagene's return on equity of 0.00% beat iBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
Adagene	N/A	N/A	N/A

iBio has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Adagene has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

iBio presently has a consensus price target of $5.00, indicating a potential upside of 314.94%. Adagene has a consensus price target of $9.50, indicating a potential upside of 179.41%. Given iBio's stronger consensus rating and higher probable upside, research analysts clearly believe iBio is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

iBio and Adagene tied by winning 7 of the 14 factors compared between the two stocks.

How does iBio compare to Tonix Pharmaceuticals?

iBio (NASDAQ:IBIO) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

iBio presently has a consensus price target of $5.00, suggesting a potential upside of 314.94%. Tonix Pharmaceuticals has a consensus price target of $24.50, suggesting a potential upside of 106.40%. Given iBio's stronger consensus rating and higher probable upside, research analysts plainly believe iBio is more favorable than Tonix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Tonix Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

7.9% of iBio shares are owned by institutional investors. Comparatively, 82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 2.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

iBio has higher earnings, but lower revenue than Tonix Pharmaceuticals. iBio is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$100K	774.94	-$33.04M	-$0.34	N/A
Tonix Pharmaceuticals	$13.11M	15.53	-$124.02M	-$12.94	N/A

In the previous week, Tonix Pharmaceuticals had 14 more articles in the media than iBio. MarketBeat recorded 16 mentions for Tonix Pharmaceuticals and 2 mentions for iBio. Tonix Pharmaceuticals' average media sentiment score of 0.71 beat iBio's score of 0.37 indicating that Tonix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tonix Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iBio has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market. Comparatively, Tonix Pharmaceuticals has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market.

iBio has a net margin of 0.00% compared to Tonix Pharmaceuticals' net margin of -548.64%. iBio's return on equity of -40.66% beat Tonix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
Tonix Pharmaceuticals	-548.64%	-68.99%	-61.31%

Summary

iBio beats Tonix Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does iBio compare to CAMP4 Therapeutics?

iBio (NASDAQ:IBIO) and CAMP4 Therapeutics (NASDAQ:CAMP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

iBio has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, CAMP4 Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

iBio has a net margin of 0.00% compared to CAMP4 Therapeutics' net margin of -2,543.74%. iBio's return on equity of -40.66% beat CAMP4 Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iBio	N/A	-40.66%	-35.78%
CAMP4 Therapeutics	-2,543.74%	-252.79%	-85.65%

iBio presently has a consensus price target of $5.00, indicating a potential upside of 314.94%. CAMP4 Therapeutics has a consensus price target of $9.56, indicating a potential upside of 125.00%. Given iBio's stronger consensus rating and higher probable upside, research analysts plainly believe iBio is more favorable than CAMP4 Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iBio	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
CAMP4 Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

iBio has higher earnings, but lower revenue than CAMP4 Therapeutics. iBio is trading at a lower price-to-earnings ratio than CAMP4 Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iBio	$100K	774.94	-$33.04M	-$0.34	N/A
CAMP4 Therapeutics	$4.22M	63.26	-$80.40M	-$2.32	N/A

7.9% of iBio shares are owned by institutional investors. 2.8% of iBio shares are owned by insiders. Comparatively, 21.7% of CAMP4 Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, CAMP4 Therapeutics had 4 more articles in the media than iBio. MarketBeat recorded 6 mentions for CAMP4 Therapeutics and 2 mentions for iBio. CAMP4 Therapeutics' average media sentiment score of 0.84 beat iBio's score of 0.37 indicating that CAMP4 Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iBio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CAMP4 Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iBio beats CAMP4 Therapeutics on 11 of the 17 factors compared between the two stocks.

Get iBio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IBIO vs. The Competition

Export

Metric	iBio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$78.78M	$3.84B	$7.15B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-3.54	14.25	275.24	25.29
Price / Sales	774.94	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	0.78	15.12	10.33	6.20
Net Income	-$33.04M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-8.02%	-4.34%	-3.32%	-2.35%
1 Month Performance	-18.03%	-0.02%	-0.41%	-2.77%
1 Year Performance	N/A	40.64%	19.21%	7.63%

iBio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IBIO iBio	1.9044 of 5 stars	$1.21 -1.6%	$5.00 +314.9%	N/A	$78.78M	$100K	N/A	100
CGEN Compugen	3.9437 of 5 stars	$2.63 +1.5%	$5.00 +90.1%	+76.4%	$244.89M	$72.76M	6.92	70	Positive News
ELDN Eledon Pharmaceuticals	1.7061 of 5 stars	$2.99 -0.7%	$10.00 +234.4%	+9.4%	$244.60M	N/A	N/A	10	Positive News
ADAG Adagene	3.8876 of 5 stars	$3.69 +1.4%	$10.00 +171.0%	+45.3%	$240.43M	$7.67M	N/A	260	News Coverage Analyst Forecast
TNXP Tonix Pharmaceuticals	4.4371 of 5 stars	$13.38 -4.3%	$24.50 +83.1%	-62.0%	$239.77M	$13.11M	N/A	50	News Coverage Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IBIO) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iBio (IBIO) Competitors

IBIO vs. CGEN, ELDN, ADAG, TNXP, and CAMP

How does iBio compare to Compugen?

Summary

How does iBio compare to Eledon Pharmaceuticals?

Summary

How does iBio compare to Adagene?

Summary

How does iBio compare to Tonix Pharmaceuticals?

Summary

How does iBio compare to CAMP4 Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iBio (IBIO) Competitors

IBIO vs. CGEN, ELDN, ADAG, TNXP, and CAMP

How does iBio compare to Compugen?

Which has more risk & volatility, CGEN or IBIO?

Which has stronger valuation and earnings, CGEN or IBIO?

Do insiders and institutionals have more ownership in CGEN or IBIO?

Does the media prefer CGEN or IBIO?

Is CGEN or IBIO more profitable?

Do analysts rate CGEN or IBIO?

Summary

How does iBio compare to Eledon Pharmaceuticals?

Is IBIO or ELDN more profitable?

Which has more risk and volatility, IBIO or ELDN?

Do insiders & institutionals believe in IBIO or ELDN?

Does the media favor IBIO or ELDN?

Do analysts rate IBIO or ELDN?

Which has stronger earnings & valuation, IBIO or ELDN?

Summary

How does iBio compare to Adagene?

Does the media refer more to IBIO or ADAG?

Do institutionals and insiders believe in IBIO or ADAG?

Which has better valuation & earnings, IBIO or ADAG?

Is IBIO or ADAG more profitable?

Which has more volatility and risk, IBIO or ADAG?

Do analysts rate IBIO or ADAG?

Summary

How does iBio compare to Tonix Pharmaceuticals?

Do analysts prefer IBIO or TNXP?

Do insiders & institutionals have more ownership in IBIO or TNXP?

Which has higher earnings and valuation, IBIO or TNXP?

Does the media favor IBIO or TNXP?

Which has more volatility and risk, IBIO or TNXP?

Is IBIO or TNXP more profitable?

Summary

How does iBio compare to CAMP4 Therapeutics?

Which has more volatility and risk, IBIO or CAMP?

Is IBIO or CAMP more profitable?

Do analysts recommend IBIO or CAMP?

Which has preferable earnings & valuation, IBIO or CAMP?

Do insiders and institutionals believe in IBIO or CAMP?

Does the media favor IBIO or CAMP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO vs. The Competition

iBio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools